SCHEMBL22492112

SCHEMBL22492112

O=C(O)[C@H]1OCCO[C@H]1c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 2/20 0.46
▸ SLC6A2 P23975 1/20 0.43
▸ ADRA1A P35348 1/20 0.43
▸ HTR2B P41595 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.43
▸ CYP2C19 P33261 3/20 0.42
▸ HTR1A P08908 3/20 0.42
▸ TSHR P16473 2/20 0.41
▸ AKR1C3 P42330 1/20 0.40
▸ AKR1C1 Q04828 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ EDNRA P25101 1/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ TP53 P04637 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22492114 1.00 EPHX1 (0.46) EPHX1SLC6A2ADRA1AHTR2BSLC6A3
SCHEMBL22492115 1.00 EPHX1 (0.46) EPHX1SLC6A2ADRA1AHTR2BSLC6A3
SCHEMBL28376946 0.79 AKR1C3 (0.41) EPHX1TSHRAKR1C3AKR1C1L3MBTL1
SCHEMBL31703382 0.79 AKR1C3 (0.41) EPHX1TSHRAKR1C3AKR1C1L3MBTL1
SCHEMBL22492107 0.76 AKR1C3 (0.46) EPHX1SLC6A2ADRA1AHTR2BSLC6A3
SCHEMBL22492109 0.76 AKR1C3 (0.46) EPHX1SLC6A2ADRA1AHTR2BSLC6A3
SCHEMBL4071198 0.76 EPHX1 (0.67) EPHX1CYP2C19TSHRAKR1C3AKR1C1
SCHEMBL6689012 0.76 EPHX1 (0.67) EPHX1CYP2C19TSHRAKR1C3AKR1C1
SCHEMBL3343090 0.76 EPHX1 (0.67) EPHX1CYP2C19TSHRAKR1C3AKR1C1
SCHEMBL1692473 0.76 EPHX1 (0.67) EPHX1CYP2C19TSHRAKR1C3AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332472-B2 Substituted piperidines as inhibitors of ubiquitin specific protease 7 LES LABORATOIRES SERVIER (FR) 2022-05-17 — — US disclosed
US-20200407363-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 LES LABORATOIRES SERVIER (FR) 2020-12-31 — — US disclosed
EP-3717482-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Les Laboratoires Servier SAS (FR) 2020-10-07 — — EP disclosed
CN-111542524-A Novel piperidinyl derivatives as inhibitors of ubiquitin-specific protease 7 法国施维雅药厂 2020-08-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332472-B2 Substituted piperidines as inhibitors of ubiquitin specific protease 7 USP7, PSMA7, PSMB7 EPHX1 2822/4885SLC6A2 4768/4885ADRA1A 2728/4885
US-20200407363-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 PSMB7, PSMA7, USP7 EPHX1 2912/4885SLC6A2 4853/4885ADRA1A 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback